Targeting splicing in prostate cancer

Antonopoulou, Effrosyni; Ladomery, Michael

Abstract

© 2018 by the authors. Licensee MDPI, Basel, Switzerland. Over 95% of human genes are alternatively spliced, expressing splice isoforms that often exhibit antagonistic functions. We describe genes whose alternative splicing has been linked to prostate cancer; namely VEGFA, KLF6, BCL2L2, ERG, and AR. We discuss opportunities to develop novel therapies that target specific splice isoforms, or that target the machinery of splicing. Therapeutic approaches include the development of small molecule inhibitors of splice factor kinases, splice isoform specific siRNAs, and splice switching oligonucleotides.

Citation

Antonopoulou, E., & Ladomery, M. (2018). Targeting splicing in prostate cancer. International Journal of Molecular Sciences, 19(5), 1287. https://doi.org/10.3390/ijms19051287

• Journal Article Type: Review
• Acceptance Date: Apr 25, 2018
• Online Publication Date: Apr 25, 2018
• Publication Date: May 1, 2018
• Journal: International Journal of Molecular Sciences
• Print ISSN: 1661-6596
• Electronic ISSN: 1422-0067
• Publisher: MDPI
• Peer Reviewed: Peer Reviewed
• Volume: 19
• Issue: 5
• Pages: 1287
• DOI: https://doi.org/10.3390/ijms19051287
• Keywords: alternative splicing, prostate cancer, VEGFA, KLF6, BCL2L2, ERG, AR, splice switching oligonucleotides, RNA interference, splice factors, splice factor kinases
• Public URL: https://uwe-repository.worktribe.com/output/870708
• Publisher URL: http://dx.doi.org/10.3390/ijms19051287